Furthering their expertise in the field of cannabinoid-based therapeutics, Zelira Therapeutics (ASX: ZLD) is set to tap into the oral care market with the launch of hemp derived toothpaste in the United States. The toothpaste formulation was created by Sprinjene CEO and Founder, Dr Sayed Abrahim who developed the oral care product which is gluten-free,
Read More
Food technology company Holista Colltech (ASX: HCT) has filed a patent for platform technology claiming to deliver fat-soluble medications which can be applied to the cannabidiol oil industry, making CBD oils 40 times more potent. If granted, the global patent can be applied to a whole range of molecules to create a water-soluble delivery system
Read More
Australian cannabis pharmaceuticals company THC Global (ASX: THC) is one major step closer to their ‘Farm to Pharma’ strategy, having been granted a Manufacture Permit from the Australian Office of Drug Control for their facility in Southport, Queensland. By securing the permit, THC Global will immediately commence production of medicinal cannabis products which have been
Read More
Australian bio-pharmaceutical developer Zelda Therapeutics (ASX: ZLD) has now fully enrolled insomnia sufferers into clinical trials where the Company aims to use cannabis as a treatment for clinically diagnosed patients. This set of trials will be completed in collaboration with the University of Western Australia (UWA) Centre for Sleep Science. The trials will aim to
Read More
Medical cannabis producer, Cann Global (ASX: CGB) is set to expand their operations in Asia after launching a new Asian-based subsidiary, allowing them to cultivate and process cannabinoid products in South-East Asia. By commencing operation in south-east Asia, the Company is best positioned to capitalise on conditions which are ideal for outdoor growing, which may
Read More
Biopharmaceuticals manufacturer MGC Pharmaceuticals (ASX: MXC) has seen significant uptake of its cannabinoid medications with prescriptions across Australia and the United Kingdom doubling to 800 patients through the month of October. The update comes as more medical practitioners prescribe phytocannabinoid-derived medications CannEpil®, which targets drug-resistant epilepsy, and MXP100 which is recommended for neurological disorders, inflammation
Read More